Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;59(9):5529-34.
doi: 10.1128/AAC.00773-15. Epub 2015 Jun 29.

Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models

Jordan R Smith  1 , Katie E Barber  1 , Jessica Hallesy  1 , Animesh Raut  1 , Michael J Rybak  2
Affiliations

Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models

Jordan R Smith et al. Antimicrob Agents Chemother. 2015 Sep.

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) isolates have arisen with reduced susceptibility to several anti-MRSA agents. Telavancin (TLV), a novel anti-MRSA agent, retains low MICs against these organisms. Our objective was to determine the MICs for TLV, daptomycin (DAP), vancomycin (VAN), and linezolid (LZD) against daptomycin-nonsusceptible (DNS) S. aureus, vancomycin-intermediate S. aureus (VISA), heteroresistant VISA (hVISA), and linezolid-resistant (LZD(r)) S. aureus. We also evaluated these agents against each phenotype in pharmacokinetic/pharmacodynamic (PK/PD) models. Seventy DNS, 100 VISA, 180 hVISA, and 25 LZD(r) MRSA isolates were randomly selected from our library and tested to determine their MICs against TLV, DAP, VAN, and LZD via broth microdilution and a Trek panel. Four isolates were randomly selected for 168-h in vitro models to evaluate treatment with TLV at 10 mg/kg of body weight/day, DAP at 10 mg/kg/day, VAN at 1 g every 12 h (q12h), and LZD at 600 mg q12h. The MIC50/90 for TLV, DAP, VAN, and LZD against 70 DNS S. aureus isolates were 0.06/0.125 μg/ml, 2/4 μg/ml, 1/2 μg/ml, and 2/2 μg/ml, respectively. Against 100 VISA isolates, the MIC50/90 were 0.06/0.125 μg/ml, 1/1 μg/ml, 4/8 μg/ml, and 1/2 μg/ml, respectively. Against 170 hVISA isolates, the MIC50/90 were 0.06/0.125 μg/ml, 0.5/1 μg/ml, 1/2 μg/ml, and 1/2 μg/ml, respectively. Against 25 LZD(r) isolates, the MIC50/90 were 0.03/0.06 μg/ml, 1/1 μg/ml, 2/2 μg/ml, and 8/8 μg/ml, respectively. The TLV MIC was >0.125 μg/ml for 10/365 (2.7%) isolates. In PK/PD models, TLV was universally bactericidal at 168 h and statistically superior to all antibiotics against DNS S. aureus strain R2334. These data further establish the potency of TLV against resistant MRSA. The model data demonstrate in vitro bactericidal activity of TLV against hVISA, VISA, DNS S. aureus, and LZD(r) S. aureus strains. Further clinical research is warranted.

PubMed Disclaimer

Figures

FIG 1
FIG 1
One hundred sixty-eight-hour one-compartment PK/PD model. Solid circles, TLV at 10 mg/kg/day; solid squares, DAP at 10 mg/kg/day; triangles, VAN at 1 g q12h; inverted triangles, LZD at 600 mg q12h; solid diamonds, growth control. Shown are R6669 hVISA (A), NJ872 VISA (B), R2334 DNS S. aureus (C), and R6246 LZDr S. aureus (D). TLV, telavancin; DAP, daptomycin; VAN, vancomycin; LZD, linezolid; VISA, vancomycin-intermediate S. aureus; hVISA, heteroresistant VISA; DNS, daptomycin-nonsusceptible; LZDr , linezolid resistant. Values in parentheses represent the MICs in μg/ml. Values are shown as the means and standard deviations.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mendes RE, Sader HS, Farrell DJ, Jones RN. 2011. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009–2010). Diagn Microbiol Infect Dis 71:93–97. doi:10.1016/j.diagmicrobio.2011.05.012. - DOI - PubMed
    1. Mendes RE, Sader HS, Farrell DJ, Jones RN. 2012. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA hospitals (2007–2009). Diagn Microbiol Infect Dis 72:113–117. doi:10.1016/j.diagmicrobio.2011.09.023. - DOI - PubMed
    1. Xiong YQ, Hady WA, Bayer AS, Chen L, Kreiswirth BN, Yang SJ. 2012. Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 56:5528–5533. doi:10.1128/AAC.00922-12. - DOI - PMC - PubMed
    1. Steed ME, Vidaillac C, Rybak MJ. 2012. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 56:955–959. doi:10.1128/AAC.05849-11. - DOI - PMC - PubMed
    1. Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN. 2015. Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States. Antimicrob Agents Chemother 59:1811–1814. doi:10.1128/AAC.04616-14. - DOI - PMC - PubMed

Publication types

MeSH terms